Vorasidenib, potentially the first targeted therapy for low-grade glioma, comes at a toxicity price.
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
CTI Biopharma sees an unlikely end to its 32-year rollercoaster existence.
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.